BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $218.25M rose 33.6% year over year, behind the +68.7% change in trailing-twelve-month revenue. Sequentially, it rose 39.5% from the prior quarter. Over 3 fiscal years it compounded at +47.8% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 7 analysts of $718.73M (-17.8%) for the fiscal year ending Dec 2026, a slowdown from the +94.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$218.25M+39.5% QoQ
Last fiscal yearDec 2025
$874.84M+94.1% YoY
LTMJun 2026
$940.61M+68.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.6%+3.9%-29.7 pp
1 year+94.1%-17.8%-111.9 pp
3-year CAGR+47.8%-2.5%-50.3 pp
5-year CAGR+4.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
874.84M USD
Year-over-year change
+94.1%
4-year CAGR
+53.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +68.7% is the lowest of 2, against a peer median of +214.0%.
  • Over three fiscal years its annual growth of +47.8% compares with a peer median of -65.1%.
BCRX Competitors
Revenue for BCRX and competitors
Company Period LTM YoY 3-year CAGR
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$940.61M USD+68.7%+47.8%
VIRVir Biotechnology, Inc.LTM Mar 2026$65.5M USD+214.0%-65.1%
PHVSPharvaris N.V.LTM Sep 2026€0 EUR——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
Peer median (excluding BCRX) —+214.0%-65.1%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.